<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00275171</url>
  </required_header>
  <id_info>
    <org_study_id>019</org_study_id>
    <nct_id>NCT00275171</nct_id>
  </id_info>
  <brief_title>rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter</brief_title>
  <official_title>The Effect of 0.1 mg Recombinant Human Thyrotropin (rhTSH) on Thyroid Radioiodine-uptake and the Degree of Goiter Reduction Following 131I-therapy, in Patients With Benign Non-toxic Nodular Goiter. A Randomized, Double-blind, Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steen Bonnema</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at clarifying (in a randomized, double-blinded design):

        1. Whether stimulation with 0.1 mg rhTSH 24, 48 or 72 hours before induction of a
           131I-tracer dosis increases the 131I uptake in patients with atoxic multinodular goitre
           and to study which time interval is the most optimal (Part I)

        2. Whether patients suffering from atoxic multinodular goitre obtains a corresponding
           goitre reduction compared with a control group when stimulating with 0.1 mg rh TSH 24,
           48 or 72 hours before 131I therapy and when reducing the thyroid radiation dose to 50 Gy
           (Part II)

      The two studies will be carried out successively on the same patient population. The 131I
      uptake will be carried out first followed by the I therapy itself. The patients are compared
      with a placebo-treated control group going through the same course of treatment, but the 131I
      dosis will be 100 Gy (standard treatment). After the 131I therapy, all patients are followed
      during one year with a regular ultrasound scan of the thyroid gland and control of the
      metabolic status. The patient satisfaction is monitored by the use of a
      visual-analogue-scale.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>An intra-individual comparison of the thyroid 131I-uptake before and after stimulation with rhTSH /placebo</measure>
    <time_frame>24 and 96 hours after tracer administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>An inter-individual comparison of the thyroid 131I uptake between those who receive placebo and those who receive rhTSH</measure>
    <time_frame>24 and 96 hours after tracer administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>An estimation of which time-interval, injecting rhTSH, that is more favourable before 131I therapy (24 hours, 48 hours or 72 hours)</measure>
    <time_frame>24 and 96 hours after tracer administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>A comparison of the degree of goiter reduction when patients are prestimulated with rhTSH and receive a thyroid 131I dose of 50 Gy or when receiving conventional 131I, receiving a thyroid dose of 100 Gy</measure>
    <time_frame>3, 6, 9 and 12 months after 131I therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A registration of adverse effects following rhTSH/placebo</measure>
    <time_frame>All adverse effects occuring within one year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction (Visual Analogue Scale) before, 3 months post 131I therapy, and at the end of follow-up (1 year).</measure>
    <time_frame>baseline, 3 and 12 months after 131I therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of TPOab or TSHRab</measure>
    <time_frame>At 12 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid function</measure>
    <time_frame>At 12 months follow up.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Nodular Goiter</condition>
  <arm_group>
    <arm_group_label>rhTSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>proceeded by 0.1 mg rhTSH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 ml isotonic saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human thyrotropin (Thyrogen)</intervention_name>
    <description>0.1 mg rhTSH administered intramuscularly</description>
    <arm_group_label>rhTSH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human TSH</intervention_name>
    <description>0.1 mg rhTSH administered intramuscularly</description>
    <arm_group_label>rhTSH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>isotonic saline = placebo</intervention_name>
    <description>0.1 mg isotonic saline injected intramuscularly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Apart from benign non-toxic goiter no other serious illness

          -  Signed proof of participation

        Exclusion Criteria:

          -  Treatment with Levothyroxine

          -  Former 131I-therapy

          -  A thyroid volume above 100 ml or a retro-clavicular component

          -  Unsafe contraception

          -  Pregnancy or breastfeeding

          -  Participation in another clinical trial

          -  Previous allergic reaction toward rhTSH

          -  Suspicion of malignancy in the thyroid gland either by clinical examination,
             laboratory findings (a raised serum calcitonin or ionized calcium)or by fine-needle
             aspiration biopsy

          -  Physically or mental condition making it impossible to participate

          -  Acute ischemic heart attach within the last 3 months

          -  Alcohol and/or drug addicts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steen J. Bonnema, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2006</study_first_submitted>
  <study_first_submitted_qc>January 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2006</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Steen Bonnema</investigator_full_name>
    <investigator_title>Consultant, phd, DMsc</investigator_title>
  </responsible_party>
  <keyword>Nontoxic nodular goiter</keyword>
  <keyword>131I therapy</keyword>
  <keyword>thyroid radioiodine uptake</keyword>
  <keyword>optimal time-interval</keyword>
  <keyword>reduced 131I activity</keyword>
  <keyword>goiter reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goiter</mesh_term>
    <mesh_term>Goiter, Nodular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

